Journal of Advanced Molecular Pharmacology and Toxicology

NANO-ENGINEERED ANTIDOTES: REVOLUTIONIZING PRECISION THERAPY IN MODERN TOXICOLOGY

Madhu Chandaka — 2026-05-16

Nano-engineered antidotes represent a transformative advancement in modern pharmacology and toxicology by integrating nanotechnology with precision medicine to improve therapeutic efficacy, target specificity, and toxicological safety. Conventional antidotal therapies often suffer from limitations such as poor bioavailability, systemic toxicity, rapid metabolism, and inadequate tissue targeting. Nanotechnology-based therapeutic systems including liposomes, polymeric nanoparticles, dendrimers, nanozymes, metallic nanoparticles, and lipid-based nanocarriers provide innovative solutions for overcoming these limitations. These nanoformulations enable controlled drug release, enhanced pharmacokinetics, selective organ targeting, and improved detoxification mechanisms against poisons, heavy metals, organophosphates, venoms, and oxidative toxicants. Recent developments in artificial intelligence-driven nanomedicine and precision toxicology have further enhanced predictive toxicological modeling and personalized antidote delivery strategies. Nano-engineered antidotes also demonstrate promising applications in neurotoxicity, hepatotoxicity, cardiotoxicity, and environmental toxicology through mechanisms involving reactive oxygen species scavenging, enzyme mimicking, and targeted molecular neutralization. However, concerns regarding nanoparticle-induced toxicity, biodistribution, long-term accumulation, immunogenicity, and regulatory challenges remain significant barriers to clinical translation. Emerging approaches such as biodegradable nanoparticles, organ-on-chip testing systems, machine learning-assisted toxicity prediction, and nano-QSAR models are reshaping the future of safe nanotherapeutics. This article comprehensively explores the pharmacological principles, toxicological implications, therapeutic applications, translational challenges, and future prospects of nano-engineered antidotes in precision toxicology. The integration of nanotechnology with pharmacology offers immense potential for developing next-generation antidotal therapies capable of achieving highly effective and patient-specific detoxification strategies in clinical medicine.

AI-DRIVEN PHARMACOLOGY: PREDICTING DRUG RESPONSES THROUGH INTELLIGENT MOLECULAR MODELING

Narender Boggula — 2026-05-16

Artificial intelligence (AI) has emerged as a transformative force in pharmacology by enabling accurate prediction of drug responses through intelligent molecular modeling, computational toxicology, and precision medicine approaches. Traditional drug discovery and pharmacological evaluation are often constrained by high costs, prolonged timelines, low success rates, and complex biological variability. AI-driven pharmacology integrates machine learning, deep learning, neural networks, molecular docking, quantitative structure–activity relationship (QSAR) modeling, and systems biology to accelerate drug development and optimize therapeutic outcomes. Advanced computational models can predict pharmacokinetics, pharmacodynamics, toxicity, molecular interactions, adverse drug reactions, and individualized treatment responses with remarkable precision. AI-assisted molecular modeling facilitates rapid screening of millions of compounds, identification of novel therapeutic targets, and optimization of lead compounds while minimizing experimental burden. Furthermore, integration of genomic, proteomic, metabolomic, and clinical datasets has enabled personalized pharmacology tailored to individual patient characteristics. Recent developments in generative AI, explainable AI, digital twins, and reinforcement learning are revolutionizing intelligent drug design and therapeutic prediction systems. Despite these advances, significant challenges remain regarding data quality, algorithmic bias, interpretability, ethical concerns, cybersecurity, and regulatory standardization. AI-driven pharmacology also faces limitations related to biological complexity, heterogeneous datasets, and translational reliability. This article comprehensively examines the principles, methodologies, applications, challenges, ethical implications, and future prospects of AI-assisted molecular modeling in modern pharmacology. The convergence of artificial intelligence with pharmacological sciences holds extraordinary potential for reshaping precision therapeutics, improving patient safety, reducing drug development failures, and accelerating the discovery of next-generation medicines for complex human diseases.

FROM VENOM TO VITAL MEDICINE: EXPLORING TOXIC COMPOUNDS AS FUTURE THERAPEUTICS

Naidu Narapusetty — 2026-05-16

Toxic compounds derived from animal venoms, poisonous plants, microorganisms, and environmental toxins have historically been associated with morbidity and mortality; however, modern pharmacology has increasingly recognized these substances as valuable sources of novel therapeutic agents. Advances in molecular biology, toxinology, proteomics, bioinformatics, and pharmacological screening have enabled scientists to isolate, characterize, and modify toxic molecules for beneficial medical applications. Venom-derived peptides, alkaloids, bacterial toxins, and marine biotoxins possess highly selective biological activities that can target ion channels, receptors, enzymes, signaling pathways, and cellular membranes with remarkable specificity. Several successful drugs including captopril, ziconotide, exenatide, and botulinum toxin have emerged directly from toxic natural compounds, demonstrating the immense therapeutic potential of toxins. Contemporary research explores the applications of toxic compounds in oncology, neurology, cardiology, pain management, infectious diseases, immunotherapy, and precision medicine. Novel technologies such as recombinant toxin engineering, nanotechnology, artificial intelligence-assisted drug discovery, and synthetic biology have further accelerated toxin-based therapeutic development. Despite significant promise, major challenges remain regarding toxicity optimization, immunogenicity, pharmacokinetics, ethical sourcing, ecological sustainability, and regulatory approval. This article comprehensively reviews the pharmacological principles, mechanisms of action, therapeutic applications, translational challenges, and future prospects of toxin-derived medicines. The transformation of dangerous toxins into life-saving therapeutics represents one of the most remarkable achievements in modern biomedical science and highlights the critical importance of interdisciplinary collaboration in advancing future drug discovery and precision therapeutics.

GREEN TOXICOLOGY AND SUSTAINABLE DRUG DEVELOPMENT: REDEFINING SAFETY IN PHARMACOLOGICAL RESEARCH

LAKSHMI ANUSHA VINJAVARAPU — 2026-05-16

Green toxicology represents an emerging interdisciplinary framework that integrates principles of environmental sustainability, green chemistry, and modern toxicological sciences to redesign drug development with reduced ecological and human health impact. Traditional pharmacological research and industrial drug manufacturing rely heavily on synthetic pathways that generate hazardous waste, employ toxic reagents, and often overlook long-term environmental persistence of pharmaceutical compounds. In contrast, green toxicology emphasizes safer-by-design principles, predictive toxicology, biodegradable drug systems, renewable raw materials, and environmentally benign synthesis strategies. The approach extends beyond conventional safety evaluation by incorporating life-cycle assessment, ecotoxicological modeling, in silico toxicity prediction, and systems-based hazard identification. Recent advances in computational toxicology, artificial intelligence, and omics technologies have significantly enhanced the predictive capacity of green toxicological frameworks, enabling early identification of hazardous molecular features and optimization of safer drug candidates. Furthermore, sustainable drug development integrates green manufacturing practices, solvent-free synthesis, biocatalysis, and nanomaterial-based eco-friendly drug delivery systems. Regulatory agencies and pharmaceutical industries are increasingly adopting sustainability metrics to minimize carbon footprint and chemical waste generation. Despite its promise, challenges remain in standardization, global regulatory harmonization, data availability, and balancing drug efficacy with environmental safety. This article explores the foundational principles, methodological advances, industrial applications, and future perspectives of green toxicology in pharmaceutical sciences. The integration of sustainability with toxicological assessment represents a paradigm shift toward safer, cleaner, and more responsible drug development practices that align with global environmental and public health goals..Green toxicology; Sustainable drug development; Green chemistry; Environmental toxicology; Predictive toxicology; Pharmaceutical sustainability; Ecotoxicology.

PHARMACOGENOMICS AND PERSONALIZED MEDICINE: TRANSFORMING DRUG SAFETY AND TOXICOLOGICAL OUTCOMES

JALAIAH M — 2026-05-16

Pharmacogenomics and personalized medicine have emerged as transformative approaches in modern healthcare, significantly improving drug safety, therapeutic efficacy, and toxicological outcomes. Traditional “one-size-fits-all” pharmacotherapy often results in adverse drug reactions, therapeutic failures, and increased healthcare burdens due to interindividual genetic variability. Pharmacogenomics integrates genomic information into clinical decision-making, enabling healthcare professionals to tailor drug selection and dosage according to a patient’s genetic profile. Variations in genes encoding drug-metabolizing enzymes, transporters, and receptors-such as CYP450 enzymes, TPMT, VKORC1, and HLA alleles-play critical roles in determining pharmacokinetic and pharmacodynamic responses. Personalized medicine utilizes these genetic insights to minimize toxicity, enhance therapeutic effectiveness, and prevent severe adverse drug reactions. Recent advances in next-generation sequencing, bioinformatics, artificial intelligence, and multi-omics technologies have accelerated the integration of pharmacogenomics into clinical practice. Pharmacogenomic-guided therapy has demonstrated substantial benefits in oncology, cardiology, psychiatry, infectious diseases, and pain management. Despite its promise, challenges remain regarding ethical concerns, regulatory frameworks, clinical implementation, healthcare disparities, data privacy, and economic feasibility. Moreover, pharmacogenomics contributes significantly to toxicology by identifying genetically susceptible individuals and predicting toxic responses before drug administration. This article explores the principles, clinical applications, technological advancements, toxicological implications, benefits, limitations, ethical considerations, and future prospects of pharmacogenomics and personalized medicine. The study emphasizes how precision therapeutics can transform healthcare systems globally by reducing adverse drug reactions and promoting safer, more individualized treatment strategies for improved patient outcomes and public health sustainability.